The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

• Make smarter investment decisions with TipRanks’ Smart Investor Picks, delivered to your inbox every week.

Top 5 Upgrades:

• TD Cowen upgraded Texas Instruments (TXN) to Buy from Hold with a price target of $245, up from $200. Texas Instruments is positioned to outperform in either a sharp or gradual recovery, the firm tells investors in a research note.

• Scotiabank upgraded Thermo Fisher (TMO) to Outperform from Sector Perform with a price target of $590, down from $605. The firm believes the “worst-case outlook” for life science tools companies has been largely factored into valuations. Scotiabank also upgraded Danaher (DHR) to Outperform from Sector Perform.

• BNP Paribas Exane upgraded WK Kellogg (KLG) to Neutral from Underperform with a $23 price target after the company entered into an agreement under which Ferrero has agreed to acquire it for $23.00 per share in cash, representing a total enterprise value of $3.1B.

• Wedbush upgraded Cinemark (CNK) to Outperform from Neutral with a price target of $37, up from $32. The firm believes the company is poised to benefit from a more consistent release slate over the next several quarters, approaches its convertible debt repayment date next month, stays ahead of competitors with theater investments, and returns cash to shareholders in 2025 with a dividend and likely with shares repurchases.

• Wedbush upgraded AMC Entertainment (AMC) to Outperform from Neutral with a price target of $4, up from $3. The firm believes AMC is poised to benefit from a more consistent release slate over the next several quarters, is positioned to gain market share in 2025 and 2026 with the most premium screens in North America and expansion plans in U.K./EU, repaid or postponed all debt that was due in 2026, relieving near-term uncertainty, and is completing what Wedbush expects to be a last major issuance for the foreseeable future, putting a significant headwind behind it.

Top 5 Downgrades:

• Scotiabank downgraded Illumina (ILMN) to Sector Perform from Outperform with a price target of $125, down from $164. The firm awaits more clarity around company-specific macro factors before again recommending the shares.

• BofA downgraded Expeditors (EXPD) to Underperform from Neutral with a price target of $118, up from $117. Containership rates are sliding rapidly from current levels given excess supply and muted demand, the firm tells investors in a research note.

• Jefferies downgraded Nutrien (NTR) to Hold from Buy with a price target of $66, up from $63. Nutrien’s positive earnings momentum in the near-term now appears discounted in the shares, while consensus revisions are likely to peak by mid-2026, the firm tells investors in a research note.

• Wells Fargo downgraded Oscar Health (OSCR) to Underweight from Equal Weight with a price target of $10, down from $16. Wells believes 2025 pricing is not adequate to cover cost trends and increasing market acuity.

• Susquehanna downgraded Boyd Gaming (BYD) to Neutral from Positive with a price target of $86, up from $76, after the company sold its 5% ownership in FanDuel to Flutter and renegotiated its market access agreement.